When I came to NYU Langone as a resident in the 1970s, it was—and still is—an outstanding medical school and hospital with wonderful people. The longer I stayed, the more I wanted to become part of its close-knit, interdisciplinary community of physicians and scientists. I still carry on the tradition that goes back to 1841, when NYU School of Medicine was founded: I’m dedicated to treating a diverse group of people, and to putting patients first.
I chose internal medicine because of my interest in a broad range of diseases. Rheumatology is my specialty, because I am especially concerned with how little we understand about immunological conditions, in which the body attacks itself.
Whether researching new treatments for heart disease or rheumatoid arthritis, I’m not only focused on the science but on making medical advances that have direct implications for my patients’ health.
In addition to my research, I am vice dean for education, faculty, and academic affairs at NYU Grossman School of Medicine.
This provider accepts the following insurance plans.
WTC Health Program
- WTC Health Program
“We’re investigating the genetic causes of many conditions, and our findings are improving patients’ lives.”Steven Abramson, MD Rheumatologist
basic arthritis research
Our lab is interested in the cytokine, growth factors, extracellular matrix proteins and integrins involved in the chondrocyte signaling pathways and molecular mechanisms that regulate the biology of chondrocytes and bone cells. Basic research is also carried out on the cellular and molecular mechanisms underlying chondrocyte differentiation and maturation. Currently we are employing global gene expression technique such as microarray to study changes in gene expression in osteoarthritis cartilage as compared to non-arthritic cartilage. We are also currently involved in characterizing the promoters of dysregulated genes in OA with promoter analyses software to characterize and study the influence of transcription factors on these genes. Furthermore, recent evidence suggests that during OA chondrocytes undergo a phenotypic modulation to hypertrophic state which are considered as degradative chondrocytes. Hypertrophic chondrocytes synthesize cartilage-degrading proteases and thus probably play a critical role in the progression of the disease. The phenotype of normal chondrocytes is stabilized by the epigenetic status of the cell such as hyper or hypo methylation of target gene promoters. This raises the question as to whether the destabilization of the chondrocytic phenotype in OA is at least, in part, the result of changes in this epigenetic status. Recently, we have undertaken to study epigenetic changes including micro RNA expression, which allows us to study the transcriptional and translational regulation of genes.
Furthermore, our laboratory has long standing interest in the functions for nitric oxide (NO) and prostaglandin E2 in the activation of MAP kinase signaling, protease synthesis and cellular death in chondrocyte and synovial fibroblast. Recently, we identified a novel latent tumor growth factor-beta1 (TGF-beta1) activating an extracellular matrix protein F-spondin. F-spondin has not been studied in differentiation of chondrocyte, endochondral ossification, cartilage matrix metabolism and pathological mineralization process. We are planning to develop an F-spondin knock out mouse to explore the functions of F-spondin and TGFb-1 in the development of OA. The fundamental knowledge obtained from these studies is crucial for understanding the pathogenesis and treatment of diseases such as osteoarthritis and rheumatoid arthritis.
Academic medicine. 2023 Sep 01; 98(9):1036-1043
Osteoarthritis & cartilage open. 2023 Sep 01; 5(3):?-?
Osteoarthritis & cartilage open. 2023 Sep ; 5(3):100379